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“I enjoyed your talk, but. . .”: Evidence-based
medicine and the scientific foundation of the
American Venous Forum
Mark H. Meissner, MD, Seattle, WashUnder a mandate from the joint council of the Society
for Vascular Surgery and the North American Chapter of
the International Society for Cardiovascular Surgery, the
American Venous Forum was founded in 1989 as an aca-
demic colloquium to facilitate the exchange of basic and
clinical research in venous and lymphatic disease. At the
time, general and vascular surgeons managed most chronic
venous disorders and the Forum was established to fulfill a
need not met by other surgical societies. The American
Venous Forum was the first surgical organization in the
United States dedicated to the study of venous disease and
remains the only organization devoted to the entire spec-
trum of venous disease, both acute and chronic, as well as
lymphatic disease.
The care of patients with venous disease has undergone
many changes since the founding of the American Venous
Forum. Although the incidence of acute deep venous
thrombosis (DVT) and chronic venous disorders have not
changed substantially in the last decade,1,2 the advent of
new drugs and other technology has fundamentally altered
patient care. The move toward less invasive procedures has
increased entrepreneurial opportunities for the develop-
ment of new technology, extended the spectrum of special-
ists involved in the treatment of venous disease, and al-
lowed marketing directly to the patient. The American
Venous Forum has accordingly evolved into a multispe-
cialty group, which, rather than narrowly focused on aca-
demic endeavors, encompasses a commitment to venous
health at the levels of research, education, awareness, and
delivery of care. However, the treatment of venous disease
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244according to scientifically sound principles remains critical,
and the founder’s vision for the American Venous Forum is
as relevant today as it was 20 years ago. The impetus for this
topic came from a foreign colleague’s question as to why
members of our society often began their comments from
the floor with “I enjoyed your talk, but . . .”. This comment
epitomizes the culture of the American Venous Forum - a
respectful, but questioning approach to the evidence. Despite
its expanded mission, a commitment to scientific integrity
remains the foundation of the organization.
Both physicians and patients are fortunate to live in an age
where science and technology are rapidly advancing the fron-
tiers of venous disease. However, we also live in a time where
new technology is conceived, approved, marketed, and often
embraced without appropriate attention to scientific princi-
ples. In following the cycle of surgery for incompetent perfo-
rating veins, O’Donnell3 called attention to the often compet-
ing interests of evidence and technology, noting that lessons
learned from the scientific evidence may be forgotten as new
technology emerges (Fig).
Many of the technological advances in the United States
are driven by industry. The pharmaceutical industry was re-
sponsible for the development of 92% of new compounds
approved by the United States Food and Drug Administra-
tion between 1980 and 1996.4 The vast majority of these
drugs do have benefits for patients, and the methodological
quality of studies sponsored by the pharmaceutical industry
appears at least equivalent to not-for-profit sponsored re-
search.4 However, systematic reviews have suggested that
studies funded by for-profit entities are more likely to yield
results favoring the trial intervention.5,6 Furthermore, indus-
try-sponsored trials are often highly focused, leaving impor-
tant clinical issues unresolved, and frequently concentrate on
short-term surrogate outcome measures.4
Medical devices account for many of the innovations in
venous disease and the pathway to market differs from that
required for the approval of new drugs and biological
agents. Devices are under the jurisdiction of the Center for
Devices and Radiological Health (CDRH) and are classi-
fied on the basis of their perceived risk. Accordingly, many
devices are approved without rigorous clinical trials. Class I
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facturing practices and quality regulation; class II devices
require special controls such as performance standards,
registries, and/or post marketing surveillance; while class
III devices require more extensive study due to a potentially
increased risk of illness or injury.7,8 New devices are gener-
ally class II or class III and are brought to market through
either a Premarket Notification (510 (k)) or Premarket
Approval (PMA) application. Although the PMA process is
more rigorous and requires clinical trials in humans, over 90%
of new devices belong to class II and are approved through the
510 (k) process, largely requiring demonstration that the
safety and effectiveness are substantially equivalent to a mar-
keted predicate device.7,8 Unfortunately, although this pro-
cess is effective in encouraging the development of new tech-
nology and does provide some mechanism for insuring safety,
it often sheds little light on effectiveness with respect to
clinically relevant outcome measures.
Evidence-based medicine is often derided in interventional-
based fields, perhaps largely due to the misconception that
it restricts clinical decision-making to randomized clinical
trials and meta-analyses. It is unrealistic to expect data from
robust randomized trials to guide every clinical question
that arises. Evidence-based medicine is better defined as
“the conscientious, explicit, and judicious use of the cur-
rent best evidence in making decisions about the care of
individual patients.”9 This specifically involves integrating
clinical expertise, the patient’s individual situation and pref-
erences, and the best available clinical evidence. Although
trial methodology is related to the quality of the evidence,
clinicians are actually most interested in reliable estimates of
the benefits and harms associated with a therapy.10 For
high quality evidence, the effects of therapy (beneficial or
Fig. An open surgical approach to ligation of incompetent perfo-
rating veins (ICPV) was developed by Linton with subsequent
modifications by Cockett. The high ulcer recurrence rate after
surgical interruption of ICPVs associated with deep venous incom-
petence, described by many groups including Saint Thomas’ Hos-
pital Unit, and lack of hemodynamic benefit demonstrated by
Bjordal were associated with decreased use of this procedure. The
advent of deep venous reconstruction and a re-emphasis on non-
surgical treatment of venous ulcers led to further decrease the use
of this surgery. Finally, the availability of a minimally invasive
approach for ligation of ICPV, pioneered by Hauer, resulted in
renewed interest and an increasing number of procedures. From
O’Donnell, TF.3 Reprinted with permission.ill) are precise and further research is unlikely to change ourconfidence in the estimate of effect. In contrast, the esti-
mated effect provided by poor quality evidence is unclear
and likely to change as better quality evidence becomes avail-
able. Based upon these considerations, the Grading of Rec-
ommendations, Assessment, Development, and Evaluation
(GRADE) working group has recommended stratifying evi-
dence into four levels based upon the level of confidence in the
estimate of effect10 (Table I).
As randomized clinical trials are less prone to bias and
are less likely to lead to false positive conclusions of efficacy,
they are clearly the gold standard for evaluating the clinical
effectiveness of a treatment. However, they may not be
appropriate for all diseases and interventions.11 Random-
ized trials may be difficult to justify when interventions are
clearly harmful or show a large beneficial treatment effect
(risk ratio 0.4) in observational studies. Treatments that
produce some survivors from a uniformly fatal condition do
not require evidence from randomized trials. Interventions
with moderate treatment effects (risk ratio 0.4-0.9) are
probably best addressed with randomized trials, while sam-
ple size requirements of those with very small treatment
effects (risk ratios 0.9-1.0) may preclude adequately pow-
ered randomized trials. Furthermore, large randomized
trials are expensive12 and pose specific problems when
applied to interventional therapies.13 The rigorous entry
criteria and attention to detail required by randomized
trials may also be difficult to extrapolate to the generalized
patient population and practice setting.
We must, therefore, often look to other sources of
evidence to guide practice. Observational studies include
those with a cohort or case control design and, in the
hierarchy of study designs, are generally assigned an inter-
mediate position between randomized trials and lesser
quality evidence such as descriptive studies, case reports,
and expert opinion.14 Such trials are often less expensive,
more expedient, and allow inclusion of a broader range of
patients.15 They may also be important in the identification
of rare adverse events associated with a therapy.5,10,11
However, in comparison to randomized trials addressing
the same topic, observational studies may underestimate, or
more commonly overestimate, treatment effects. The fatal
biases of some observational designs, such as the worse
Table I. Quality of evidence
Quality of evidence Description
High Further research unlikely to change
confidence in estimate of effect
Moderate Further research likely to impact confidence
in estimate of effect and may change
estimate
Low Further research very likely to impact
confidence in estimate of effect and likely
to change estimate
Very Low Estimate of effect is very uncertain
Adapted from GRADE Working Group. Grading quality of evidence and
strength of recommendations.10outcomes associated with nonconcurrent, historic controls,
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quality evidence, uniform rejection of properly collected
observational data is unwarranted. Among 45 topics for
which both randomized and nonrandomized trials had
been performed, results of the two methodologies were
highly correlated (correlation coefficient  0.83) with re-
spect to estimates of efficacy, although the magnitude of
treatment effects tended to be larger in nonrandomized
trials.17 Others have found that the results of randomized
controlled trials and well-designed observational studies are
remarkably similar and that such studies do not necessarily
overestimate the magnitude of effect.11,14,15
Finally, although methodology is a determinant of qual-
ity, other factors such as study design and execution, consis-
tency of the estimate of effect across studies, and directness are
also important.10 Consideration of these factors can decrease
the quality of randomized trials or increase the quality of
observational studies as shown in Table II.18
To be useful in guiding decisions about individual
patients, studies must not only be scientifically sound, they
must be clinically relevant. Direct evidence is the most
certain evidence and comes from studies with subjects,
treatments, and outcome measures similar to the question
of interest. Unfortunately, much research in vascular dis-
ease in general, and venous disease in particular, continues
to rely on indirect evidence, particularly through the use of
surrogate outcome measures. Clinically important out-
comes measure how a treatment improves a patient’s func-
tion, symptoms, quality of life, or survival.19 Some have
even suggested that concepts such as “clinically relevant” or
“clinically important” be replaced with alternative terms
such as “patient” or “humanly” important outcomes.20 In
contrast, surrogate outcome measures are substitutes for
outcomes of importance to the patient or health care sys-
tem. Such measures may include laboratory, radiographic,
or other diagnostic tests, physical signs, physiologic param-
eters, and similar substitutes for important outcome mea-
sures.19 Surrogate outcomes often have the advantages of
being easier, less costly, or less invasive to measure, may
require a shorter period of follow-up, and may require
smaller sample sizes. However, they must be used and
Table II. Factors affecting evidence quality
Factors lowering the quality of
randomized trials
Factors increasing the quality
of observational studies
Poor study methods and
execution (Blinding,
concealed allocation,
follow-up) Large magnitude of effect
Inconsistency across trials All confounders reduce effect
Indirect evidence (Use of
surrogate outcomes, lack of
direct comparisons between
treatments) Dose-response relationship
Imprecise or sparse results
Reporting bias
Adapted from Guyatt G, et al.18interpreted with caution.Implicit in the use of surrogate measures is that they
accurately predict, rather than are simply correlated with,
the outcome of interest.19 While a perfect surrogate is an
intermediate along the only pathway to the clinical out-
come, other pathways may exist and a treatment may affect
the surrogate measure and the important clinical outcome
through different pathways or independent mechanisms.21
Validation of a surrogate measure requires not only that the
clinical benefit of treatment can be estimated from its effect
on the surrogate (predictive criteria) but also that the net
treatment effect on the clinical outcome is entirely ac-
counted for by its effect on the surrogate (capture crite-
ria)21,22 (Table III). While the correlation between surro-
gate and clinical outcomes may be easy to demonstrate,
proving predictive utility often requires large randomized
clinical trials or meta-analyses evaluating the treatment
effects on both outcomes.
Unfortunately, surrogate outcome measures are often
based on an unproven assumed relationship between the
surrogate marker and an accepted clinical outcome.23 Such
measures are occasionally chosen in an effort to prove the
superiority of one treatment modality or device with re-
spect to an outcome of minimal importance to the patient.
For example, it is certainly possible that small, statistically
significant but clinically irrelevant differences in bruising
after a superficial venous procedure are related to overall
patient satisfaction or quality of life, but this is likely an
unproven assumption. Perhaps more importantly, surro-
gate outcomes may not only be misleading, they may lead
to harm. Failures of surrogate endpoints to capture unan-
ticipated ill effects of treatment on clinical outcomes
abound in all fields of medicine.24 For example, premature
ventricular contractions and mortality after myocardial in-
farction are related and several antiarrythmic drugs were
approved on the basis of their ability to suppress ventricular
ectopy as a surrogate endpoint. Unfortunately, randomized
clinical trials subsequently demonstrated that several drugs,
although effective at suppressing arrhythmias, actually in-
crease mortality.23
Surrogate outcome are often markers of related clinical
outcomes, but in general they contribute to poor quality
clinical evidence. They may be appropriate in early feasibility
studies, in screening the clinical potential of new interven-
tions, and in phase II clinical trials.19,21 However, studies
using surrogate outcome should not alter the standard of care.
Such studies should serve as the basis for further trials using
Table III. Criteria for valid surrogate outcome measures
Well established relationship between surrogate and clinical
outcome
Surrogate changes in response to treatment should predict
patient benefit
Treatment effect on clinical outcome entirely explained by effect
on surrogate
Clinical benefit based on effects of treatment on the surrogate is
independent of the nature of the treatment
Adapted from Kassai B, et al.22clinically relevant (or patient important) outcomes.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 Meissner 247Such outcome measures are particularly attractive in the
field of chronic venous disease, where the measurement of
clinically relevant outcomes may require years of follow-up.
Surrogate outcomes in venous disease include closure rates,
questionable clinical outcomes such as bruising, ultrasound
scan-derived outcomes such as the prevention or correction of
reflux, and hemodynamic measures. Although potentially re-
lated, the more important clinical outcomes include relief of
symptoms, varicose vein recurrence, and ulcer recurrence.
Clinical outcomes can also be captured in validated instru-
ments such as the Venous Clinical Severity Score (VCSS).25,26
However, even such clinical measures may fail to capture the
entire burden of disease (physical, psychological, social) and
the efficacy of any treatment modality is perhaps best mea-
sured by its impact on quality of life. A number of generic and
venous disease-specific quality of life instruments27-30 are
available, but have generally been underutilized in evaluating
new technologies.
Consider for example the treatment of saphenous vein
reflux. Endovenous thermal ablation techniques have largely
replaced high ligation and stripping in the management of
great and small saphenous reflux in the United States. As may
be appropriate, most early studies focused on rates of saphe-
nous occlusion. Several randomized trials31-35 (Table IV)
have subsequently addressed early efficacy and safety, suggest-
ing that the endovenous techniques are at least equivalent to
high ligation and stripping, with potential advantages with
respect to early postoperative pain. Superficial venous disease
is, however, a chronic disorder, and data concerning long-
term efficacy of the procedures with respect to recurrence and
quality of life is limited. Intermediate term (1-3 years) out-
comes of fewer than 100 participants in randomized trials have
been reported in the literature.36,37 Although it would be
reasonable to expect a shift in focus to long term, clinically
relevant outcomes, such as quality of life or varicose vein
recurrence, such data does not appear to be immediately
forthcoming. A MEDLINE search of the terms “ablation”
and “saphenous vein” returned 29 manuscripts added bet-
ween January 2007 and January 2008. A review of the avail-
able abstracts disclosed 10 of these papers to include poten-
tially relevant data regarding thermal ablation of the great or
small saphenous veins. These included two randomized clini-
cal trials, three cohort studies, and five case series. Follow-up
intervals ranged from 24 hours to 4 years, only one study
presenting outcome beyond 1 year. The majority of studies
continued to report venous occlusion as the primary outcome
measure. Clinically relevant outcome measures were included
as a primary outcome (ulcer healing) in only one randomized
trial,38 as a secondary outcome (Aberdeen Varicose Vein
Severity Score (AVSS), Medical Outcomes Study Short Form
36, VCSS) in one randomized trial,34 and as a reported
outcome (VCSS, AVSS) in three of the remaining stud-
ies.26,39,40 Although the introduction of new technology may
require feasibility studies, we are now at a point in the evolu-
tion of these procedures where we should move beyond case
series and surrogate outcome measures to investigation of
long-term clinically important outcomes.We are indeed fortunate to be involved with the care of
patients with venous disease at a time where there is a large
amount of interest in the medical community as well as a
number of technological advances. Unfortunately, the ap-
propriate care of patients with venous disease now depends
on the cooperative efforts of clinicians, federal regulatory
agencies, industry, and health care payers. Although en-
couraging the development of new technology, the current
regulatory environment does not favor proof of clinically
relevant efficacy. While investment in scientifically sound,
but unrequired clinical research, may be too much to
expect from the medical industry, it may also be unreason-
able to expect insurers to pay for unproven technology.
As it is often becoming incumbent on the medical
community to validate the clinical utility of new technol-
ogy, the scientific foundations of our medical societies
become increasingly important. Societies such as the Amer-
ican Venous Forum must not only continue to promote
high quality basic and clinical research, they must also insist
both that our clinical interventions are validated and
evidence-based and that they be appropriately reimbursed.
Although surrogate measures may be appropriate for early
feasibility studies, a dialog with industrial sponsors regard-
ing the necessity of well-conducted studies with clinically
relevant, patient important endpoints should be encour-
aged. Formal, evidence-based practice guidelines for the
care of patients with chronic venous disease should be
developed in preference to those based only on expert
opinion. The American College of Chest Physicians has
successfully established an evidence-based standard of care
for acute venous disease41 and similar initiatives need to be
undertaken for chronic venous disease. Not only will such
guidelines serve to insure high quality care of patients with
venous disorders, they will also provide third party payers
with a recognized standard of care. Finally, fellowships in
outcomes research should be incorporated into our re-
search awards in order to develop a core of clinical scientists
devoted to evidence-based practice.
As physicians, we also have obligations to our individual
patients and to society. All of us should commit to evidence-
based practice, understanding that this does not require sub-
mitting to “a tyranny of the evidence”, but integrating our
own clinical expertise, the patient’s values and preferences,
and the best evidence available from the literature. We further
Table IV. Endovenous ablation – randomized trials
Author Year Procedure N Follow-up
Rasmussen et al34 2007 HL/S vs EVL 121 6 mo
Stotter et al42 2006 HL/S vs RF vs
cryostripping
120 1 year
Lurie et al36 2005 HL/S vs RF 85 1-2 yrs
Perala et al37 2005 HL/S vs RF 28 3 yrs
De Medieros et al31 2005 HL/S vs EVL 20 60 days
Hinchliffe et al32 2006 HL/S vs RF 16 10 days
HL/S, High ligation and stripping; EVL, endovenous laser ablation; RF,
radiofrequency ablation.have an obligation to know the data regarding the treatments
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associated risks and benefits. We should also demand some
proof of clinically relevant efficacy before subjecting our pa-
tients to costly new therapies of unproven benefit. Finally, we
need to individually participate in scientifically questioning the
existing evidence and generating new evidence - “I enjoyed
your talk, but . . . .”.
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